Interaction of G2019S LRRK2 and metabolic syndrome in a two-hit mouse model of Parkinson’s disease: LRRK2-driven systemic depletion of pyrimidine nucleosides.

Publication date: Jul 08, 2026

G2019S LRRK2 is the most common cause of familial Parkinson’s disease (PD) and is associated with sporadic PD, arising from the interplay of genetic predisposition, environmental exposure and aging. Metabolic syndrome is implicated as a risk factor for PD, but the interaction between G2019S LRRK2 and metabolic stress in disease pathogenesis remains unclear. We employed high-fat diet (HFD) feeding to induce metabolic syndrome in aged mutant LRRK2 mice, followed by system-wide characterization, including metabolomic or proteomic profiling, and bulk or single-nucleus RNA sequencing. We find that thymidine and deoxyuridine levels are consistently reduced across tissues in G2019S LRRK2 knockin mice accompanied by increased hepatic expression of thymidine phosphorylase. HFD exposure further unmasks disruptions in purine and energy metabolism in brain and lung of G2019S LRRK2 knockin mice, with midbrain astrocytes and oligodendrocytes exhibiting the most pronounced impairment in oxidative phosphorylation transcriptional pathways. Our findings demonstrate that pre-existing metabolic syndrome unmasks widespread disruptions in systemic nucleotide and energy metabolism and exacerbates mitochondrial dysfunction in G2019S LRRK2 knockin mice. This conditional “two-hit” phenotype underscores the critical role of environmental factors, such as diet, in revealing metabolic vulnerabilities associated with PD-linked genetic backgrounds, and provides potential metabolic targets for therapeutic intervention in PD.

Open Access PDF

Concepts Keywords
Astrocytes Diet
G2019s Environmental
Genetic Exposure
Parkinsons G2019s
Thymidine Genetic
Hit
Interaction
Knockin
Lrrk2
Metabolic
Mice
Parkinson
Pd
Syndrome
Systemic

Semantics

Type Source Name
disease MESH metabolic syndrome
disease MESH Parkinson’s disease
disease MESH genetic predisposition
drug DRUGBANK Deoxythymidine
pathway REACTOME Metabolism
pathway KEGG Oxidative phosphorylation
disease MESH mitochondrial dysfunction
disease MESH Dis
pathway REACTOME Reproduction
disease MESH included
disease MESH movement disorder
disease MESH tremor
disease MESH bradykinesia
drug DRUGBANK L-Leucine
disease MESH autosomal dominant
disease MESH obesity
disease MESH hyperglycemia
disease MESH hypertension
disease MESH dyslipidemia
disease MESH heart disease
disease MESH stroke
disease MESH type 2 diabetes
disease MESH prediabetes
disease MESH strains
disease MESH fed
disease MESH anxiety
disease MESH gliosis
disease MESH inflammation
drug DRUGBANK Isoxaflutole
disease MESH weight gain
disease MESH neuroinflammation
drug DRUGBANK Dopamine
drug DRUGBANK L-Tyrosine
drug DRUGBANK Serine
pathway KEGG Endocytosis
pathway REACTOME Autophagy
drug DRUGBANK Phosphoenolpyruvate
drug DRUGBANK NADH
drug DRUGBANK ATP
pathway KEGG Purine metabolism
drug DRUGBANK Nebularine
drug DRUGBANK Thymine
drug DRUGBANK Uracil
drug DRUGBANK Propylthiouracil
drug DRUGBANK Phosphate ion
pathway KEGG Pyrimidine metabolism
drug DRUGBANK Activated charcoal
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Fructose
pathway REACTOME Glycolysis
drug DRUGBANK Citric Acid
disease MESH PPP
pathway REACTOME Nucleotide biosynthesis
drug DRUGBANK Inosine
drug DRUGBANK Hypoxanthine
pathway REACTOME Pentose phosphate pathway
disease MESH fibrosis
disease MESH insulin resistance
pathway KEGG Insulin resistance
drug DRUGBANK Albendazole
drug DRUGBANK Water
disease MESH decapitation
drug DRUGBANK Sucrose
disease MESH Body weight
drug DRUGBANK Coenzyme M
drug DRUGBANK Ethanol
drug DRUGBANK Edetic Acid
drug DRUGBANK Isoflurane
drug DRUGBANK Nitrogen
disease MESH Image
disease MESH Neurodegenerative Diseases
pathway REACTOME Neurodegenerative Diseases
pathway KEGG Parkinson disease
drug DRUGBANK L-Asparagine
disease MESH Nam
pathway REACTOME TRP channels
disease MESH injury
disease MESH metabolic disease
disease MESH tumorigenesis
disease MESH cancer
disease MESH cardiovascular disease
disease MESH mitochondrial myopathy
disease MESH Park
disease MESH lung cancer
disease MESH cognitive impairment
drug DRUGBANK Uric Acid
disease MESH dementia
pathway REACTOME Glucose metabolism
disease MESH viral infection

Original Article

(Visited 38 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *